Akari Therapeutics Appoints Torsten Hombeck As CFO
Portfolio - People | Dec 16, 2024 | EIN
Akari Therapeutics, a biotechnology company listed on Nasdaq, has appointed Torsten Hombeck, Ph.D., as its new Chief Financial Officer effective December 16, 2024. Dr. Hombeck brings extensive experience with more than 20 years in biotechnology, finance, and M&A, coupled with clinical and product development expertise. Previously serving as Akari's CFO, he is well-acquainted with its operations and strategic goals. Dr. Hombeck's prior roles include Chief Financial roles at Aspira Womens Health and Promethera Biosciences. Akari Therapeutics is advancing its first-in-class ADC platform and investigational therapy nomacopan, with pre-clinical research focused on geographic atrophy (GA). The company emphasizes its intent to progress its proprietary platforms and augment shareholder value under Dr. Hombeck's financial leadership. The press release includes a cautionary note on forward-looking statements, highlighting risks and uncertainties inherent in biopharmaceutical company operations.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- United States – Akari Therapeutics operates with a presence in the U.S., and its CFO brings experience from multiple U.S.-based biotech companies.
- United Kingdom – The company, Akari Therapeutics, is headquartered in London, indicating its UK relevance.
Industry
- Biotechnology – The article discusses Akari Therapeutics, a biotech company focused on therapies for autoimmune, oncology, and inflammatory diseases, indicating relevance to the biotech industry.
- Pharmaceuticals – Akari Therapeutics is involved in drug development and has investigational therapies in its pipeline, aligning it with the pharmaceutical industry.
Financials
- $50 million – The amount raised by Torsten Hombeck during his previous tenure as CFO of Akari Therapeutics.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Akari Therapeutics, Plc | Target Company | Company | A biotechnology company developing therapies for autoimmune, oncology, and inflammatory diseases. |
| Torsten Hombeck, Ph.D. | Chief Financial Officer | Person | A seasoned biotech executive with over 20 years of experience, recently reappointed as CFO of Akari Therapeutics. |
| Aspira Womens Health, Inc. | Past Employer | Company | A Nasdaq listed commercial-stage diagnostics company focusing on gynecologic health outcomes. |
| Promethera Biosciences | Past Employer | Company | A company where Dr. Hombeck held roles in commercial and strategic positions. |